Literature DB >> 28166142

Detection and Viability of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Multiparametric PET/CT-MRI Study.

Vincent Dunet1, Nermin Halkic, John O Prior, Anass Anaye, Reto A Meuli, Christine Sempoux, Alban Denys, Sabine Schmidt.   

Abstract

PURPOSE: The aim of this study was to compare combined gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA)-enhanced and diffusion-weighted (DW) MRI with IV contrast-enhanced F-FDG PET/CT to detect and assess the viability of colorectal liver metastases (CLMs) after neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: After NAC, 45 patients with CLMs were prospectively enrolled and underwent combined Gd-EOB-DTPA-enhanced and DW-MRI and contrast-enhanced F-FDG PET/CT. Forty patients subsequently underwent surgery based on intraoperative ultrasound, which served as the reference standard for the presence of CLMs. The number of metastases detected by each technique was then compared. In 69 resected metastases, the SUVmean and SUVmax, mean and maximum target-to-background ratio (TBR), total lesion glycolysis, metabolic tumor volume, and mean and minimum apparent diffusion coefficient (ADC) were examined to identify correlations with the corresponding tumor viability (TV) determined from histological specimens.
RESULTS: Intraoperative ultrasound revealed 153 CLMs, 122 of which were resected. The detection rate of MRI and contrast-enhanced F-FDG PET/CT were similar (P = 0.61). The SUVmax and minimum ADC were negatively correlated (r = -0.34, P = 0.005) on preoperative imaging after NAC. However, TV was significantly correlated with the maximum TBR (r = 0.33, P = 0.006) and mean TBR (r = 0.37, P = 0.002), but not with the minimum ADC (r = -0.02, P = 0.9) or mean ADC (r = 0.01, P = 0.9).
CONCLUSIONS: Combined Gd-EOB-DTPA-enhanced and DW-MRI and contrast-enhanced F-FDG PET/CT allow confident detection of CLMs, but only F-FDG PET metrics are associated with TV after NAC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28166142     DOI: 10.1097/RLU.0000000000001538

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases.

Authors:  Daniel Fadaei Fouladi; Manijeh Zarghampour; Pallavi Pandey; Ankur Pandey; Farnaz Najmi Varzaneh; Mounes Aliyari Ghasabeh; Pegah Khoshpouri; Ihab R Kamel
Journal:  Eur Radiol       Date:  2019-06-17       Impact factor: 5.315

Review 2.  Current status of surgical treatment of colorectal liver metastases.

Authors:  Feng Xu; Bin Tang; Tian-Qiang Jin; Chao-Liu Dai
Journal:  World J Clin Cases       Date:  2018-11-26       Impact factor: 1.337

3.  Treatment effect of conversion therapy and its correlation with VEGF expression in unresectable rectal cancer with liver metastasis.

Authors:  Ge Hou; Rui Song; Jun Yang; Yanling Zhang; Chenhu Xiao; Cheng Wang; Jinjin Yuan; Ting Chai; Zongwen Liu
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

4.  Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Vincent Dunet; Nermin Halkic; Christine Sempoux; Nicolas Demartines; Michael Montemurro; John O Prior; Sabine Schmidt
Journal:  Eur Radiol       Date:  2020-08-26       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.